The research carried out by the Spanish association is aimed at understanding the genetic factor behind the development of Pulmonary Arterial Hypertension or PAH. This kind of hereditary PAH comes from a genetic mutation. A family history has been identified in 6% of patients. The mortality rate is 10% to 20%.
Project Objectives :
5 Spanish hospitals, 200 patients and their family are participating in the research program.
The funding of the Air Liquide Foundation has been used to buy testing equipment for blood samples and to pay researchers.
The Asociación Nacional de Hipertensión Pulmonar (website in spanish), founded in 2005, is recognized of public utility in Spain. Its work consists in advancing the diagnosis of pulmonary arterial hypertension and limiting the negative consequences of this disease. Miniplug: Research on pulmonary arterial hypertension in Spain.